Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.

Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, Sudhan DR, Guerrero-Zotano AL, Croessmann S, Guo Y, Ericsson PG, Lee KM, Nixon MJ, Schwarz LJ, Sanders ME, Dugger TC, Cruz MR, Behdad A, Cristofanilli M, Bardia A, O'Shaughnessy J, Nagy RJ, Lanman RB, Solovieff N, He W, Miller M, Su F, Shyr Y, Mayer IA, Balko JM, Arteaga CL
Nat Commun. 2019 10 (1): 1373

PMID: 30914635 · PMCID: PMC6435685 · DOI:10.1038/s41467-019-09068-2

MeSH Terms (32)

Aminopyridines Animals Antineoplastic Agents, Hormonal Antineoplastic Combined Chemotherapy Protocols Breast Neoplasms Circulating Tumor DNA Cyclin-Dependent Kinase 4 Cyclin-Dependent Kinase 6 Cyclin D1 Drug Resistance, Neoplasm Female Fulvestrant High-Throughput Nucleotide Sequencing Humans MCF-7 Cells Mice Mutation Naphthalenes Piperazines Progression-Free Survival Proportional Hazards Models Protein Kinase Inhibitors Purines Pyrazoles Pyridines Quinolines Quinoxalines Receptor, Fibroblast Growth Factor, Type 1 Receptor, Fibroblast Growth Factor, Type 2 Receptors, Estrogen Signal Transduction Xenograft Model Antitumor Assays

Connections (1)

This publication is referenced by other Labnodes entities:

Links